SCHEMBL24977302

SCHEMBL24977302

COc1ccc(COc2cc(Cl)cc(OC)c2C(C)=O)cc1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 2/20 0.52
MRGPRX4 Q96LA9 2/20 0.49
MAOA P21397 4/20 0.49
MAOB P27338 4/20 0.49
KCNA3 P22001 1/20 0.48
POLB P06746 3/20 0.47
KDM4E B2RXH2 3/20 0.47
LMNA P02545 2/20 0.47
MEN1 O00255 1/20 0.47
GAA P10253 1/20 0.47
MAPT P10636 1/20 0.47
SMN1; SMN2 Q16637 2/20 0.47
NPC1 O15118 1/20 0.47
RAB9A P51151 1/20 0.47
CYP3A4 P08684 2/20 0.47
USP2 O75604 1/20 0.47
MAPK1 P28482 1/20 0.47
MTNR1A P48039 1/20 0.46
MTNR1B P49286 1/20 0.46
HDAC8 Q9BY41 2/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30800444 0.86 KMT2A (0.52) KMT2AMAOAMAOBKCNA3POLB
SCHEMBL24977661 0.86 KMT2A (0.52) KMT2AMAOAMAOBKCNA3POLB
SCHEMBL29788601 0.82 MAOB (0.57) KMT2AMAOBPOLBKDM4EMAPT
SCHEMBL1971024 0.82 MAOB (0.57) KMT2AMAOBPOLBKDM4EMAPT
SCHEMBL26608385 0.80 MTNR1A (0.46) KMT2AMAOAMAOBKCNA3POLB
SCHEMBL24936291 0.80 KMT2A (0.45) KMT2AMRGPRX4MAOAMAOBKCNA3
SCHEMBL29632579 0.80 KMT2A (0.45) KMT2AMRGPRX4MAOAMAOBKCNA3
SCHEMBL31507316 0.80 NPC1 (0.48) KMT2AMAOBKCNA3POLBMAPT
SCHEMBL26670607 0.80 NPC1 (0.48) KMT2AMAOBKCNA3POLBMAPT
SCHEMBL23327143 0.79 MAPK1 (0.53) KMT2AKDM4ELMNAMEN1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230310423-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2023-10-05 US disclosed
US-20230310423-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2023-10-05 US disclosed
US-11707462-B2 Checkpoint kinase 1 (CHK1) inhibitors and uses thereof BOUNDLESS BIO, INC. (US) 2023-07-25 US disclosed
US-11707462-B2 Checkpoint kinase 1 (CHK1) inhibitors and uses thereof BOUNDLESS BIO, INC. (US) 2023-07-25 US disclosed
US-20230026313-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF BOUNDLESS BIO, INC. 2023-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310423-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF CHEK1, CHEK2, RAD1 KMT2A 1630/4885MRGPRX4 3596/4885MAOA 4832/4885
US-11707462-B2 Checkpoint kinase 1 (CHK1) inhibitors and uses thereof CHEK1, CHEK2, RAD1 KMT2A 1630/4885MRGPRX4 3596/4885MAOA 4832/4885
US-20230026313-A1 CHECKPOINT KINASE 1 (CHK1) INHIBITORS AND USES THEREOF CHEK1, CHEK2, RAD1 KMT2A 1630/4885MRGPRX4 3596/4885MAOA 4832/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.